_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,relations,step_1_select_the_valid_relations,step_2a_copy__paste_only_the_words_from_the_sentence_that_express_the_relation_you_selected_in_step1,step_2b_if_you_selected_none_in_step_1_explain_why,b1,b2,e1,e2,expdec,rel-type,sent_id,sentence,term1,term2
502251728,7/11/2014 14:56:41,,1320765574,7/11/2014 14:56:26,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],acute treatment,n/a,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 14:57:52,,1320766079,7/11/2014 14:57:39,neodev,1,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],NIFEDIPINE,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:22:50,,1320778852,7/11/2014 15:22:13,neodev,1,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],in the acute treatment of,n/a,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:24:15,,1320779521,7/11/2014 15:23:36,instagc,1,13763729,USA,"","",75.182.89.225,[TREATS],[TREATS],SUBLINGUAL NIFEDIPINE treatment of SYSTEMIC HYPERTENSION,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:30:03,,1320781628,7/11/2014 15:28:44,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,[TREATS],[TREATS],acute treatment,Related by Treatment,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:30:48,,1320781852,7/11/2014 15:30:38,instagc,1,27753923,GBR,"","",188.29.78.53,[LOCATION],[LOCATION],Efficacy SUBLINGUAL,n/a,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:34:23,,1320783395,7/11/2014 15:33:46,prodege,1,28049280,USA,NC,Macclesfield,71.50.150.205,[TREATS],[TREATS],acute treatment,n/a,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:34:34,,1320783486,7/11/2014 15:33:56,vivatic,1,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],acute treatment of,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:41:17,,1320786043,7/11/2014 15:40:56,neodev,1,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],in the acute treatment,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 15:59:21,,1320794374,7/11/2014 15:59:01,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the acute treatment of,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 16:15:41,,1320799925,7/11/2014 16:14:00,elite,1,28276268,USA,CA,San Diego,76.88.95.100,[TREATS],[TREATS],acute treatment,acute treatment,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 16:27:38,,1320803411,7/11/2014 16:27:18,zoombucks,1,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 16:35:26,,1320806165,7/11/2014 16:35:07,instagc,1,28301350,GBR,K4,Plymouth,78.145.138.230,[TREATS],[TREATS],acute treatment,N/A,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 16:49:29,,1320810467,7/11/2014 16:48:59,neodev,1,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],in the acute treatment of,N/a,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251728,7/11/2014 16:52:31,,1320811318,7/11/2014 16:51:58,instagc,1,21777979,USA,GA,Warner Robins,174.78.194.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],SUBLINGUAL NIFEDIPINE SYSTEMIC HYPERTENSION,na,95,47,115,67,1,RO-may_treat,907907-FS1,"Beer N, Gallegos I, Cohen A et al. Efficacy of SUBLINGUAL NIFEDIPINE in the acute treatment of SYSTEMIC HYPERTENSION",SYSTEMIC HYPERTENSION,SUBLINGUAL NIFEDIPINE
502251729,7/11/2014 14:49:50,,1320762769,7/11/2014 14:49:41,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[LOCATION],[LOCATION],WOLFRAM,x,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 14:55:19,,1320765025,7/11/2014 14:55:09,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],optic,N/A,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 14:56:52,,1320765622,7/11/2014 14:56:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,n/a,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:22:12,,1320778416,7/11/2014 15:21:52,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterized by,n/a,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:26:20,,1320780256,7/11/2014 15:25:47,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],characterized,n/a,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:30:05,,1320781631,7/11/2014 15:29:42,instagc,1.0,27753923,GBR,"","",188.29.78.53,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],neurodegenerative disorder,n/a,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:32:03,,1320782283,7/11/2014 15:31:14,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES] [ASSOCIATED_WITH],"[CAUSES]
[ASSOCIATED_WITH]",characterized by,na,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:32:40,,1320782506,7/11/2014 15:32:02,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],characterized by,Looks to be a symptom,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:49:07,,1320788780,7/11/2014 15:48:43,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],characterized by,N/A,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 15:51:47,,1320790706,7/11/2014 15:50:17,instagc,1,22653569,USA,TX,Frisco,99.122.166.44,[SYMPTOM],[SYMPTOM],WOLFRAM SYNDROME neurodegenerative disorder characterized by DIABETES INSIPIDUS,na,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 16:05:49,,1320796346,7/11/2014 16:04:38,prodege,1,17334212,CAN,NB,Fredericton,142.162.42.73,[SYMPTOM],[SYMPTOM],WOLFRAM SYNDROME characterized by DIABETES INSIPIDUS,N/A,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 16:08:30,,1320797489,7/11/2014 16:07:34,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",rare diffuse neurodegenerative disorder,rare diffuse neurodegenerative disorder,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 16:18:01,,1320800812,7/11/2014 16:17:47,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],characterized,N/A,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 16:25:47,,1320802890,7/11/2014 16:25:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM],[SYMPTOM],characterized by,N/A,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251729,7/11/2014 16:31:29,,1320804548,7/11/2014 16:29:16,prodege,1.0,12635833,CAN,"","",47.55.233.55,[CAUSES] [MANIFESTATION],"[CAUSES]
[MANIFESTATION]",characterized by DIABETES INSIPIDUS,N/A,85,0,102,15,1,RO-has_manifestation,906382-FS1,"WOLFRAM SYNDROME (WFS) is a rare diffuse neurodegenerative disorder characterized by DIABETES INSIPIDUS diabetes mellitus, optic atrophy, deafness, and a wide variety of central nervous system abnormalities.",DIABETES INSIPIDUS,WOLFRAM SYNDROME
502251730,7/11/2014 14:52:12,,1320763812,7/11/2014 14:51:42,tremorgames,1,17552229,GBR,A2,Edgware,31.54.207.221,[CAUSES],[CAUSES],developed,lected [NONE,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 14:52:24,,1320763890,7/11/2014 14:52:06,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CAUSES],[CAUSES],developed,N/A,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 14:55:22,,1320765044,7/11/2014 14:54:41,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],phosphate,NONE,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 14:56:14,,1320765370,7/11/2014 14:56:04,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],but Hyp,n/a,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:11:57,,1320773441,7/11/2014 15:11:24,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],developed,n/a,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:28:41,,1320781015,7/11/2014 15:28:14,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],developed,N/A,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:29:52,,1320781534,7/11/2014 15:28:50,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],developed,na,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:32:01,,1320782255,7/11/2014 15:31:26,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[CAUSES],[CAUSES],developed,Seems to be a cause.,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:34:06,,1320783206,7/11/2014 15:33:57,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CONTRAINDICATES],[CONTRAINDICATES],"primary spongiosa,",n/a,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:45:05,,1320787122,7/11/2014 15:44:34,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],WT BONE explanted into Hyp mice developed RICKETS,N/A,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:46:33,,1320787637,7/11/2014 15:46:03,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],developed,n/a,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:50:16,,1320789560,7/11/2014 15:49:24,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[CAUSES],[CAUSES],WT BONE explanted Hyp mice developed RICKETS,na,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 15:59:25,,1320794417,7/11/2014 15:58:14,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],explanted into Hyp mice developed,N/A,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 16:23:18,,1320802220,7/11/2014 16:22:53,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],developed,N/A,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251730,7/11/2014 16:28:50,,1320803801,7/11/2014 16:28:03,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[CAUSES],[CAUSES],WT BONE developed RICKETS,n/a,0,42,6,48,1,RO-disease_has_primary_anatomic_site,902183-FS1,"WT BONE explanted into Hyp mice developed RICKETS and osteomalacia, but Hyp bone explanted into WT mice displayed persistent osteomalacia and abnormalities in the primary spongiosa, indicating that both phosphate and PHEX independently regulate extracellular matrix mineralization.",WT BONE,RICKETS
502251731,7/11/2014 14:51:09,,1320763377,7/11/2014 14:50:59,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 14:52:41,,1320763994,7/11/2014 14:52:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[IS_A],[IS_A],biochemical,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:02:09,,1320767983,7/11/2014 15:01:26,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],their place at diagnosis,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:06:18,,1320770364,7/11/2014 15:04:33,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis and treatment of,n/a,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:31:02,,1320781925,7/11/2014 15:30:29,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],place at diagnosis and treatment,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:31:55,,1320782235,7/11/2014 15:31:44,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CAUSES],[CAUSES],current state,n/a,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:32:14,,1320782342,7/11/2014 15:31:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[LOCATION],[LOCATION],their place,n/a,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:36:48,,1320784614,7/11/2014 15:35:16,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION] [DIAGNOSE_BY_TEST_OR_DRUG] [TREATS],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]
[LOCATION]",biochemical markers of BONE turnover and their place at diagnosis and treatment of,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:44:33,,1320786963,7/11/2014 15:43:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[LOCATION],[LOCATION],BONE their place OSTEOPOROSIS,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 15:48:08,,1320788282,7/11/2014 15:47:12,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],biochemical markers,na,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 16:10:54,,1320798551,7/11/2014 16:10:23,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],their place at diagnosis,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 16:12:35,,1320799064,7/11/2014 16:10:20,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],BONE turnover and their place at treatment OSTEOPOROSIS,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 16:17:46,,1320800706,7/11/2014 16:17:31,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[LOCATION],[LOCATION],place,N/A,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 16:23:21,,1320802228,7/11/2014 16:22:31,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[PREVENTS] [TREATS],"[TREATS]
[PREVENTS]",turnover diagnosis treatment,turnover diagnosis treatment,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251731,7/11/2014 16:50:43,,1320810783,7/11/2014 16:50:20,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[LOCATION],[LOCATION],BONE OSTEOPOROSIS,na,97,157,100,168,1,RO-has_finding_site,905499-FS1,The aim of this paper is to present the current state of knowledge on the biochemical markers of BONE turnover and their place at diagnosis and treatment of OSTEOPOROSIS,BONE,OSTEOPOROSIS
502251732,7/11/2014 14:50:39,,1320763138,7/11/2014 14:50:31,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],Benotti,z,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 14:50:49,,1320763231,7/11/2014 14:50:24,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CAUSES],[CAUSES],responses in,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 14:52:15,,1320763836,7/11/2014 14:50:47,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],MYXEDEMA,NONE,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 14:57:28,,1320765883,7/11/2014 14:57:19,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MYXEDEMA INTRAVENOUS THYROXINE,n/a,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 15:02:45,,1320768329,7/11/2014 15:02:19,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],responses,n/a,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 15:33:45,,1320782976,7/11/2014 15:32:46,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[TREATS],[TREATS],metabolic responses to doses,n/a,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 15:35:18,,1320783935,7/11/2014 15:34:24,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],responses in MYXEDEMA large doses of INTRAVENOUS L THYROXINE,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 15:36:58,,1320784659,7/11/2014 15:36:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],large doses of,n/a,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 15:43:25,,1320786603,7/11/2014 15:42:56,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],to large doses of,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 15:51:38,,1320790562,7/11/2014 15:51:18,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],large doses of,n/a,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 16:11:14,,1320798644,7/11/2014 16:10:55,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],responses to large doses of,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 16:24:15,,1320802453,7/11/2014 16:23:06,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[TREATS],[TREATS],Acute responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 16:27:17,,1320803291,7/11/2014 16:26:57,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],responses large doses,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 16:31:05,,1320804493,7/11/2014 16:30:29,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],large doses,N/A,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251732,7/11/2014 16:40:28,,1320807593,7/11/2014 16:39:51,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CONTRAINDICATES] [DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]
[CONTRAINDICATES]",large doses,large doses,79,106,86,128,1,RO-may_treat,907952-FS1,"2]  Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in MYXEDEMA to large doses of INTRAVENOUS L THYROXINE",MYXEDEMA,INTRAVENOUS L THYROXINE
502251733,7/11/2014 14:47:49,,1320762023,7/11/2014 14:47:14,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],epileptic,NONE,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 14:51:22,,1320763468,7/11/2014 14:51:00,tremorgames,1.0,17552229,GBR,A2,Edgware,31.54.207.221,[LOCATION],[LOCATION],persons,n,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 14:53:24,,1320764187,7/11/2014 14:53:14,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"epilepsies,",N/A,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 15:02:18,,1320768085,7/11/2014 15:01:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,"There is no relations, they are both examples of epileptic seizure listed",317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 15:28:06,,1320780839,7/11/2014 15:26:07,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[CAUSES],[CAUSES],"situation related seizures,",n/a,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 15:31:25,,1320782007,7/11/2014 15:30:05,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[OTHER],[OTHER],"related seizures,",Synonyms,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 15:34:05,,1320783197,7/11/2014 15:32:46,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],related,na,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 15:45:38,,1320787369,7/11/2014 15:45:06,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"incidence rates per year and per 100,000 persons for undermined EPILEPSIES for isolated SEIZURES",N/A,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 15:53:43,,1320792112,7/11/2014 15:51:48,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"related seizures, isolated SEIZURES",na,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 16:03:53,,1320795703,7/11/2014 16:03:11,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],by type of epileptic syndrome,n/a,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 16:28:48,,1320803778,7/11/2014 16:28:26,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[NONE],[NONE],N/A,Different diseases,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 16:34:37,,1320805960,7/11/2014 16:34:12,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[SYMPTOM],[SYMPTOM],incidence rates per year,N/A,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 16:44:52,,1320809136,7/11/2014 16:44:12,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [ASSOCIATED_WITH],"[DIAGNOSE_BY_TEST_OR_DRUG]
[ASSOCIATED_WITH]","for situation related seizures,","for situation related seizures,",317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 16:51:42,,1320811064,7/11/2014 16:51:05,neodev,1.0,18517457,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],by type of epileptic syndrome were,N/a,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251733,7/11/2014 16:51:57,,1320811196,7/11/2014 16:51:18,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[NONE],[NONE],na,na,317,251,324,260,-1,RO-has_definitional_manifestation,904884-FS1,"The incidence rates per year and per 100,000 persons by type of epileptic syndrome were 1.7 for idiopathic and 13.6 for symptomatic localization related epilepsies, 5.6 for idiopathic and 1.1 for symptomatic generalized epilepsies, 1.9 for undermined EPILEPSIES 29.0 for situation related seizures, 18.3 for isolated SEIZURES and 0.3 for television epilepsies.",SEIZURES,EPILEPSIES
502251734,7/11/2014 14:47:30,,1320761903,7/11/2014 14:47:20,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],DEFECTS,nnmnnm,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 14:49:25,,1320762588,7/11/2014 14:48:40,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[MANIFESTATION],[MANIFESTATION],result,n/a,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 14:54:07,,1320764482,7/11/2014 14:53:33,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],massive,NONE,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:08:47,,1320771538,7/11/2014 15:07:54,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[CAUSES],[CAUSES],result from,n/a,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:29:28,,1320781322,7/11/2014 15:29:04,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],can result from,N/A,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:35:25,,1320784019,7/11/2014 15:35:10,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CONTRAINDICATES],[CONTRAINDICATES],DEFECTS BONES,n/a,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:41:56,,1320786190,7/11/2014 15:41:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],can result from,N/A,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:50:12,,1320789528,7/11/2014 15:48:16,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[CAUSES],[CAUSES],can result from,n/a,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:55:28,,1320793016,7/11/2014 15:53:27,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[MANIFESTATION],[MANIFESTATION],SEGMENTAL DEFECTS IN BONES can result from CONGENITAL MALFORMATION OR NON UNION FRACTURES,N/A,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:56:51,,1320793551,7/11/2014 15:55:26,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEGMENTAL DEFECTS IN BONES can result from CONGENITAL MALFORMATION,na,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 15:58:53,,1320794225,7/11/2014 15:58:34,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],can result from,n/a,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 16:00:49,,1320794914,7/11/2014 16:00:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[MANIFESTATION],[MANIFESTATION],can result from,N/A,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 16:15:15,,1320799826,7/11/2014 16:14:54,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],result,N/A,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 16:34:29,,1320805820,7/11/2014 16:33:54,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],"can result from tumor removal,","can result from tumor removal,",6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251734,7/11/2014 16:34:33,,1320805928,7/11/2014 16:33:36,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[SYMPTOM],[SYMPTOM],SEGMENTAL DEFECTS IN BONES can result from CONGENITAL MALFORMATION OR NON UNION FRACTURES,n/a,6,80,31,125,1,RO-has_finding_site,905335-FS1,"Large SEGMENTAL DEFECTS IN BONES can result from tumor removal, massive trauma, CONGENITAL MALFORMATION OR NON UNION FRACTURES",SEGMENTAL DEFECTS IN BONES,CONGENITAL MALFORMATION OR NON UNION FRACTURES
502251735,7/11/2014 14:51:15,,1320763428,7/11/2014 14:50:48,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[LOCATION],[LOCATION],nematodes,n,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 14:54:15,,1320764563,7/11/2014 14:53:45,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],resistant,n/a,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 14:56:30,,1320765510,7/11/2014 14:55:48,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],LEGIONELLA,NONE,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 15:23:30,,1320779271,7/11/2014 15:22:51,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEGIONELLA,n/a,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 15:34:29,,1320783422,7/11/2014 15:34:09,instagc,1.0,27753923,GBR,"","",188.29.78.53,[MANIFESTATION],[MANIFESTATION],LEGIONELLA INFECTION,n/a,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 15:38:30,,1320785112,7/11/2014 15:37:57,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],LEGIONELLA INFECTION LEGIONELLA,N/A,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:17:11,,1320800307,7/11/2014 16:16:41,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],resistant,N/A,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:17:32,,1320800486,7/11/2014 16:17:04,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[PREVENTS],[PREVENTS],LEGIONELLA INFECTION resistant LEGIONELLA,na,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:25:54,,1320802909,7/11/2014 16:25:12,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[PART_OF],[PART_OF],were resistant to,N/A,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:32:11,,1320804792,7/11/2014 16:30:49,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],LEGIONELLA INFECTION LEGIONELLA,n/a,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:38:24,,1320807007,7/11/2014 16:37:51,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CONTRAINDICATES] [ASSOCIATED_WITH],"[CONTRAINDICATES]
[ASSOCIATED_WITH]",were resistant,were resistant,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:50:44,,1320810791,7/11/2014 16:50:06,neodev,1.0,18517457,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],prior to to,N/a,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:53:24,,1320811593,7/11/2014 16:53:19,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:58:02,,1320813422,7/11/2014 16:56:53,clixsense,1,8100278,USA,FL,Orlando,98.70.77.97,[PREVENTS],[PREVENTS],nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA,N/a,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251735,7/11/2014 16:59:18,,1320813934,7/11/2014 16:58:31,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],prior to LEGIONELLA INFECTION were resistant to LEGIONELLA,N/A,47,47,56,66,-1,RO-has_causative_agent,903796-FS1,"However, nematodes fed bifidobacteria prior to LEGIONELLA INFECTION were resistant to LEGIONELLA",LEGIONELLA,LEGIONELLA INFECTION
502251736,7/11/2014 14:46:37,,1320761558,7/11/2014 14:45:54,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],THORACIC,NONE,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 14:49:29,,1320762650,7/11/2014 14:49:19,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],THORACIC,m,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 14:55:08,,1320764967,7/11/2014 14:54:53,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],the,N/A,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 14:57:05,,1320765713,7/11/2014 14:56:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was foreground,n/a,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 15:04:10,,1320769026,7/11/2014 15:02:47,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,there is no obvious connection stated,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 15:11:16,,1320773165,7/11/2014 15:09:34,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[PART_OF],[PART_OF],in the foreground,n/a,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 15:26:35,,1320780341,7/11/2014 15:25:51,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],was in the foreground,N/A,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 15:27:38,,1320780684,7/11/2014 15:26:05,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],foreground,na,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 15:36:05,,1320784324,7/11/2014 15:35:54,instagc,1.0,27753923,GBR,"","",188.29.78.53,[LOCATION],[LOCATION],THORACIC FORM OF SARCOIDOSIS,n/a,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 15:40:14,,1320785660,7/11/2014 15:39:28,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY,N/A,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 16:07:48,,1320797291,7/11/2014 16:07:04,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[IS_A],[IS_A],THORACIC FORM OF SARCOIDOSIS was in BILATERAL HILAR ADENOPATHY,N/A,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 16:12:59,,1320799207,7/11/2014 16:11:07,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[LOCATION],[LOCATION],was in the foreground,was in the foreground,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 16:16:40,,1320800145,7/11/2014 16:16:22,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],foreground,N/A,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 16:27:23,,1320803342,7/11/2014 16:27:01,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[CAUSES],[CAUSES],was in the foreground,N/A,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251736,7/11/2014 16:50:04,,1320810607,7/11/2014 16:49:30,neodev,1.0,18517457,GBR,"","",86.29.147.112,[PART_OF],[PART_OF],mild in 2 cases,N/a,96,28,121,55,-1,RO-has_manifestation,906106-FS1,"In each of the patients the THORACIC FORM OF SARCOIDOSIS was in the foreground (in 6 cases mild BILATERAL HILAR ADENOPATHY in 2 cases only unilateral hilar adenopathy, in 18 cases typical BHL syndrome sometimes with tumorous adenopathy and in 7 cases out of the 18, hilar adenopathy and mottling in the lungs.",BILATERAL HILAR ADENOPATHY,THORACIC FORM OF SARCOIDOSIS
502251737,7/11/2014 14:45:52,,1320761332,7/11/2014 14:45:42,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],characterized,NONE,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 14:48:39,,1320762335,7/11/2014 14:47:01,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],characterized,n/a,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 14:54:29,,1320764637,7/11/2014 14:54:18,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],often,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 14:55:14,,1320765004,7/11/2014 14:54:58,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 15:21:51,,1320778172,7/11/2014 15:20:35,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],characterized by,na,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 15:36:16,,1320784388,7/11/2014 15:35:48,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],characterized,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 15:49:26,,1320789025,7/11/2014 15:48:55,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],EPIDERMAL NEVUS SYNDROME characterized by DISTINCTIVE SKIN LESIONS,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 15:49:59,,1320789416,7/11/2014 15:49:08,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],characterized by,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 15:52:15,,1320791034,7/11/2014 15:51:58,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],characterized by,n/a,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 16:15:49,,1320799942,7/11/2014 16:15:04,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[SYMPTOM],[SYMPTOM],characterized by DISTINCTIVE SKIN LESIONS,na,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 16:25:11,,1320802737,7/11/2014 16:24:45,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[SYMPTOM],[SYMPTOM],characterized,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 16:25:55,,1320802922,7/11/2014 16:25:39,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],characterized,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 16:29:15,,1320803950,7/11/2014 16:27:10,prodege,1.0,12635833,CAN,"","",47.55.233.55,[SYMPTOM],[SYMPTOM],characterized by DISTINCTIVE SKIN LESIONS,N/A,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 16:35:06,,1320806074,7/11/2014 16:34:30,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],characterized by,characterized by,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251737,7/11/2014 16:49:28,,1320810464,7/11/2014 16:48:00,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],EPIDERMAL NEVUS SYNDROME DISTINCTIVE SKIN LESIONS,na,75,4,98,27,1,RO-has_finding_site,905337-FS1,The EPIDERMAL NEVUS SYNDROME is a neurocutaneous disorder characterized by DISTINCTIVE SKIN LESIONS and often serious somatic and central nervous system (CNS) abnormalities.,DISTINCTIVE SKIN LESIONS,EPIDERMAL NEVUS SYNDROME
502251738,7/11/2014 14:50:47,,1320763227,7/11/2014 14:50:40,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TUBERCULOSIS,z,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 14:53:31,,1320764235,7/11/2014 14:53:18,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 15:07:53,,1320771092,7/11/2014 15:06:19,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[PREVENTS],[PREVENTS],replaced by,n/a,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 15:23:35,,1320779281,7/11/2014 15:22:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],contemporary skin tests for TUBERCULOSIS PURIFIED PROTEIN DERIVATIVe.,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 15:28:49,,1320781082,7/11/2014 15:27:40,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],skin tests,na,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 15:38:37,,1320785130,7/11/2014 15:37:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],tuberculiN PURIFIED PROTEIN DERIVATIVe.,n/a,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 15:42:25,,1320786272,7/11/2014 15:41:46,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],replaced by,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 15:51:19,,1320790311,7/11/2014 15:50:44,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],skin tests for,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:11:37,,1320798770,7/11/2014 16:11:15,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],In contemporary skin tests for,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:13:53,,1320799454,7/11/2014 16:12:35,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],tests for TUBERCULOSIS has been by tuberculiN PURIFIED PROTEIN DERIVATIVe.,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:28:26,,1320803650,7/11/2014 16:28:03,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],skin tests,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:30:06,,1320804226,7/11/2014 16:29:49,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],skin tests,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:30:49,,1320804386,7/11/2014 16:30:15,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[NONE],[NONE],n/a,Parts of the words are missing.,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:33:52,,1320805296,7/11/2014 16:33:08,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [CONTRAINDICATES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CONTRAINDICATES]",has been replaced by tuberculiN,has been replaced by tuberculiN,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251738,7/11/2014 16:37:35,,1320806778,7/11/2014 16:35:08,clixsense,1,6355977,NLD,07,Amsterdam,46.129.42.165,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],In tests for TUBERCULOSIS tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.,N/A,31,101,42,128,1,RO-may_diagnose,906547-FS1,"In contemporary skin tests for TUBERCULOSIS Koch's, or old, tuberculin has been replaced by tuberculiN PURIFIED PROTEIN DERIVATIVe.",TUBERCULOSIS,N PURIFIED PROTEIN DERIVATIV
502251739,7/11/2014 14:57:11,,1320765744,7/11/2014 14:57:00,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],ANKYLOSING,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 14:57:16,,1320765780,7/11/2014 14:57:09,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],SPONDYLOARTHROPATHIES,NONE,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 15:36:17,,1320784421,7/11/2014 15:35:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],SPONDYLOARTHROPATHIES ANKYLOSING SPONDYLITIS,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 15:36:59,,1320784662,7/11/2014 15:36:49,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],hallmark SPONDYLOARTHROPATHIES,n/a,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 15:41:45,,1320786156,7/11/2014 15:41:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[IS_A],[IS_A],especially in,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 15:42:18,,1320786243,7/11/2014 15:40:59,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[SYMPTOM],[SYMPTOM],Involvement of joints,n/a,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 15:45:15,,1320787192,7/11/2014 15:42:59,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[SYMPTOM] [CAUSES],"[CAUSES]
[SYMPTOM]",especially in,I did not select none,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 15:46:02,,1320787483,7/11/2014 15:43:48,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],especially in,n/a,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:04:08,,1320795788,7/11/2014 16:02:22,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[SYMPTOM],[SYMPTOM],hallmark of SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:14:47,,1320799726,7/11/2014 16:14:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],especially in,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:26:20,,1320803027,7/11/2014 16:25:55,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[PART_OF],[PART_OF],especially in,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:27:57,,1320803482,7/11/2014 16:27:39,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],hallmark,N/A,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:39:49,,1320807408,7/11/2014 16:39:06,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SPONDYLOARTHROPATHIES ANKYLOSING SPONDYLITIS,na,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:41:58,,1320808097,7/11/2014 16:41:14,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS],[TREATS],is a hallmark,is a hallmark,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251739,7/11/2014 16:52:57,,1320811443,7/11/2014 16:51:35,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,94,58,115,78,-1,RO-has_manifestation,906306-FS1,Involvement of the sacroiliac joints is a hallmark of the SPONDYLOARTHROPATHIES especially in ANKYLOSING SPONDYLITIS,ANKYLOSING SPONDYLITIS,SPONDYLOARTHROPATHIES
502251740,7/11/2014 14:47:18,,1320761826,7/11/2014 14:47:09,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[CONTRAINDICATES],[CONTRAINDICATES],other,kjj,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 14:57:07,,1320765721,7/11/2014 14:56:31,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],REACTIONS,NONE,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 14:57:55,,1320766100,7/11/2014 14:57:29,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],are rare phenomenon,n/a,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:02:24,,1320768155,7/11/2014 15:01:35,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],ALLERGIC REACTIONS,na,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:07:36,,1320770985,7/11/2014 15:07:09,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[OTHER],[OTHER],compared,N/A,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:10:32,,1320772677,7/11/2014 15:09:57,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,both are examples,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:33:25,,1320782799,7/11/2014 15:33:14,instagc,1.0,27753923,GBR,"","",188.29.78.53,[LOCATION],[LOCATION],ALLERGIC REACTIONS,n/a,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:38:31,,1320785103,7/11/2014 15:37:40,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[SYMPTOM],[SYMPTOM],venom.,n/a,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:43:25,,1320786614,7/11/2014 15:41:50,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],ALLERGIC REACTIONS ALLERGIES TO BEE AND wasp venom.,N/A,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:44:13,,1320786925,7/11/2014 15:43:25,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[IS_A],[IS_A],ALLERGIES,N/A,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:45:36,,1320787328,7/11/2014 15:44:02,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[OTHER],[OTHER],when compared to,different types,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 15:53:53,,1320792244,7/11/2014 15:52:31,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],ALLERGIC REACTIONS to ALLERGIES TO,Two allergic reactions to different things.,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 16:04:42,,1320795953,7/11/2014 16:03:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],compared to,N/A,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 16:20:31,,1320801434,7/11/2014 16:19:42,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[CONTRAINDICATES],[CONTRAINDICATES],ALLERGIC REACTIONS ants are a phenomenon ALLERGIES BEE AND wasp,na,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251740,7/11/2014 16:21:07,,1320801643,7/11/2014 16:20:38,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],compared,N/A,40,121,57,140,-1,RO-cause_of,900125-FS1,"In Switzerland, unlike other countries, ALLERGIC REACTIONS to ants are a rare phenomenon when compared to the well known ALLERGIES TO BEE AND wasp venom.",ALLERGIC REACTIONS,ALLERGIES TO BEE AND
502251741,7/11/2014 14:49:12,,1320762516,7/11/2014 14:48:27,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],"detection,",NONE,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 14:56:48,,1320765610,7/11/2014 14:56:36,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],managemnt,N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 15:05:23,,1320769784,7/11/2014 15:04:53,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"detection, diagnosis, and managemnt",N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 15:32:45,,1320782533,7/11/2014 15:32:02,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"suppression test for detection, diagnosis,",n/a,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 15:35:15,,1320783898,7/11/2014 15:34:35,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"suppression test for the detection, diagnosis, and managemnt of",N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 15:35:27,,1320784029,7/11/2014 15:34:50,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"detection,",na,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 15:40:23,,1320785709,7/11/2014 15:39:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,n/a,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 15:49:22,,1320788968,7/11/2014 15:48:05,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"detection,",n/a,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:15:46,,1320799938,7/11/2014 16:15:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"test for the detection, diagnosis, and managemnt of",N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:16:38,,1320800139,7/11/2014 16:16:07,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"DEXAMETHASONE suppression test the detection, DEPRESSION",na,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:19:25,,1320801171,7/11/2014 16:17:56,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"DEXAMETHASONE test for detection, of DEPRESSION",N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:28:02,,1320803509,7/11/2014 16:27:24,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[TREATS],[TREATS],managemnt of,N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:30:22,,1320804284,7/11/2014 16:30:07,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test,N/A,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:36:16,,1320806405,7/11/2014 16:35:10,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEXAMETHASONE test of DEPRESSION,na,82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251741,7/11/2014 16:45:58,,1320809470,7/11/2014 16:44:53,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"detection, diagnosis, and managemnt","detection, diagnosis, and managemnt",82,4,91,16,1,RO-may_diagnose,906827-FS1,"The DEXAMETHASONE suppression test for the detection, diagnosis, and managemnt of DEPRESSION",DEPRESSION,DEXAMETHASONE
502251742,7/11/2014 14:47:08,,1320761749,7/11/2014 14:46:55,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],symptoms,hjhh,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 14:51:42,,1320763604,7/11/2014 14:51:23,tremorgames,1.0,17552229,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],HYPERTENSION,b: If you selected [NO,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 14:52:25,,1320763919,7/11/2014 14:52:11,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in a for,n/a,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 14:57:25,,1320765854,7/11/2014 14:57:12,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],physician,N/A,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 15:01:33,,1320767717,7/11/2014 15:00:43,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],investigate,na,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 15:02:29,,1320768185,7/11/2014 15:02:22,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],HYPERTENSION,NONE,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 15:06:28,,1320770462,7/11/2014 15:05:23,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[MANIFESTATION],[MANIFESTATION],recurrence of symptoms,N/A,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 15:12:51,,1320773791,7/11/2014 15:11:18,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[MANIFESTATION],[MANIFESTATION],recurrent,n/a,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 15:27:25,,1320780606,7/11/2014 15:26:47,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HYPERTENSION undergone an operation for PHAEOCHROMOCYTOMA,N/A,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 15:34:41,,1320783538,7/11/2014 15:34:30,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],HYPERTENSION in,n/a,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 16:15:03,,1320799790,7/11/2014 16:14:36,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[SYMPTOM],[SYMPTOM],symptoms HYPERTENSION undergone an operation PHAEOCHROMOCYTOMA,na,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 16:17:54,,1320800775,7/11/2014 16:16:47,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG] [CAUSES],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",has previously undergone,has previously undergone,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 16:19:55,,1320801318,7/11/2014 16:19:06,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SYMPTOM],[SYMPTOM],symptoms,N/A,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 16:21:51,,1320801797,7/11/2014 16:21:20,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[SYMPTOM],[SYMPTOM],previously undergone an operation,N/A,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251742,7/11/2014 16:25:05,,1320802711,7/11/2014 16:24:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in a patient who,N/A,31,103,42,119,1,RO-disease_may_have_finding,902902-FS1,The recurrence of symptoms and HYPERTENSION in a patient who has previously undergone an operation for PHAEOCHROMOCYTOMA should alert the physician to the need to investigate for recurrent tumour.,HYPERTENSION,PHAEOCHROMOCYTOMA
502251743,7/11/2014 14:48:33,,1320762299,7/11/2014 14:48:21,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[CONTRAINDICATES],[CONTRAINDICATES],Stevens,jjk,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 14:55:33,,1320765090,7/11/2014 14:55:23,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],alTHALIDOMIDE,NONE,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 14:56:24,,1320765473,7/11/2014 14:56:14,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],experience,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 15:08:32,,1320771421,7/11/2014 15:08:10,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[TREATS],[TREATS],treatment,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 15:25:31,,1320779890,7/11/2014 15:24:16,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],alTHALIDOMIDE treatment of CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 15:28:12,,1320780874,7/11/2014 15:27:25,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],treatment of the,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 15:32:29,,1320782407,7/11/2014 15:32:19,instagc,1.0,27753923,GBR,"","",188.29.78.53,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],alTHALIDOMIDE treatment,n/a,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 15:35:59,,1320784275,7/11/2014 15:35:27,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n/a,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 15:51:57,,1320790829,7/11/2014 15:51:39,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment,n/a,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 16:00:39,,1320794879,7/11/2014 16:00:12,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],in the treatment of,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 16:01:14,,1320795020,7/11/2014 16:00:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],in the treatment of,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 16:16:21,,1320800090,7/11/2014 16:16:05,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 16:27:50,,1320803462,7/11/2014 16:26:58,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[TREATS],[TREATS],alTHALIDOMIDE in the treatment of CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 16:33:47,,1320805284,7/11/2014 16:33:10,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[TREATS],[TREATS],in the treatment,N/A,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251743,7/11/2014 16:46:29,,1320809622,7/11/2014 16:46:00,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS],[TREATS],in the treatment,in the treatment,75,39,121,49,1,RO-may_treat,907641-FS1,"Stevens RJ, Andujar C, Edwards CJ et alTHALIDOMIDE in the treatment of the CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS experience in sixteen consecutive patients.",CUTANEOUS MANIFESTATIONS OF LUPUS ERYTHEMATOSUS,THALIDOMIDE
502251744,7/11/2014 14:48:47,,1320762368,7/11/2014 14:48:34,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],duration,nn,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 14:53:32,,1320764253,7/11/2014 14:52:16,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[LOCATION],[LOCATION],chronic,NONE,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 14:53:48,,1320764369,7/11/2014 14:53:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"headache,",N/A,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 14:53:54,,1320764392,7/11/2014 14:53:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 15:20:33,,1320777333,7/11/2014 15:19:53,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 15:31:43,,1320782143,7/11/2014 15:31:29,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],long duration,n/a,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 15:37:56,,1320784922,7/11/2014 15:37:20,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Primary chronic headaches of long duration include CHRONIC TENSION TYPE HEADACHE HEMICRANIA CONTINUA,N/A,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 15:52:30,,1320791326,7/11/2014 15:51:19,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[IS_A],[IS_A],Primary chronic headaches of long duration include,N/A,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:03:09,,1320795439,7/11/2014 16:02:53,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,n/a,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:10:19,,1320798408,7/11/2014 16:09:07,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],CHRONIC TENSION TYPE HEADACHE and HEMICRANIA CONTINUA,N/A,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:10:22,,1320798413,7/11/2014 16:09:39,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],Primary chronic headaches of long duration include,N/A,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:21:59,,1320801842,7/11/2014 16:21:22,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[SYMPTOM],[SYMPTOM],"new daily persistent headache, and HEMICRANIA CONTINUA",na,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:29:35,,1320804074,7/11/2014 16:28:57,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],include,N/A,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:44:09,,1320808882,7/11/2014 16:42:00,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"new daily persistent headache,","new daily persistent headache,",69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251744,7/11/2014 16:48:58,,1320810360,7/11/2014 16:48:20,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,N/a,69,134,97,152,-1,RO-has_definitional_manifestation,904651-FS1,"Primary chronic headaches of long duration include chronic migraine, CHRONIC TENSION TYPE HEADACHE new daily persistent headache, and HEMICRANIA CONTINUA",CHRONIC TENSION TYPE HEADACHE,HEMICRANIA CONTINUA
502251745,7/11/2014 14:47:13,,1320761780,7/11/2014 14:46:38,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],revealed,NONE,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 14:48:20,,1320762218,7/11/2014 14:47:56,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],in,nmn,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 14:51:22,,1320763470,7/11/2014 14:51:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 14:52:06,,1320763770,7/11/2014 14:51:29,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],and,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:04:32,,1320769247,7/11/2014 15:03:59,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[OTHER],[OTHER],NYD SP16,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:09:56,,1320772274,7/11/2014 15:09:18,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[LOCATION],[LOCATION],in the,n/a,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:32:15,,1320782350,7/11/2014 15:31:42,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],variable expression in patients,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:33:54,,1320783065,7/11/2014 15:31:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],in the TESTES,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:35:47,,1320784176,7/11/2014 15:35:19,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],TESTES SPERMATOGENIC ARREST,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:36:19,,1320784437,7/11/2014 15:36:07,instagc,1.0,27753923,GBR,"","",188.29.78.53,[LOCATION],[LOCATION],abnormal expression,n/a,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:41:27,,1320786112,7/11/2014 15:40:25,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,it is just a part of the body,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:43:32,,1320786646,7/11/2014 15:42:19,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[LOCATION],[LOCATION],in the TESTES,n/a,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:48:03,,1320788257,7/11/2014 15:46:34,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in,n/a,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 15:58:21,,1320794076,7/11/2014 15:56:46,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],TESTES of patients with SPERMATOGENIC ARREST,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251745,7/11/2014 16:30:42,,1320804362,7/11/2014 16:30:23,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SYMPTOM],[SYMPTOM],syndrome,N/A,112,204,117,223,1,RO-has_finding_site,905466-FS1,Further analysis of abnormal expression in infertile male patients revealed complete absence of NYD SP16 in the TESTES of patients with Sertoli cell only syndrome and variable expression in patients with SPERMATOGENIC ARREST,TESTES,SPERMATOGENIC ARREST
502251746,7/11/2014 14:46:30,,1320761521,7/11/2014 14:46:21,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],HYPERTENSION,Big break,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 14:56:59,,1320765664,7/11/2014 14:56:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],clinical,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 15:00:29,,1320767202,7/11/2014 14:59:31,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in severe,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 15:29:58,,1320781582,7/11/2014 15:29:27,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],in severe,n/a,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 15:30:00,,1320781602,7/11/2014 15:29:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],in severe,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 15:34:06,,1320783200,7/11/2014 15:33:43,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PART_OF],[PART_OF],in severe,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 15:35:06,,1320783837,7/11/2014 15:34:12,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[SYMPTOM],[SYMPTOM],Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 15:52:56,,1320791617,7/11/2014 15:52:41,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[SYMPTOM],[SYMPTOM],in severe,n/a,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 16:24:28,,1320802515,7/11/2014 16:24:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",in,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 16:45:00,,1320809173,7/11/2014 16:44:36,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],ARTERIAL HYPERTENSION HYPERTENSIVE ENCEPHALOPATHY,n/a,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 16:51:58,,1320811197,7/11/2014 16:51:43,neodev,1.0,18517457,GBR,"","",86.29.147.112,[SYMPTOM],[SYMPTOM],in severe,N/a,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 16:53:18,,1320811581,7/11/2014 16:53:12,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 16:56:52,,1320812872,7/11/2014 16:55:54,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[SYMPTOM],[SYMPTOM],Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY,n/a,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 17:01:11,,1320814835,7/11/2014 16:59:19,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[SYMPTOM],[SYMPTOM],Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251746,7/11/2014 17:01:53,,1320815193,7/11/2014 17:00:31,prodege,1,11616695,GBR,H2,Skelmersdale,92.28.88.16,[PART_OF],[PART_OF],in severe,N/A,13,45,33,71,1,RO-disease_has_finding,901903-FS1,Treatment of ARTERIAL HYPERTENSION in severe HYPERTENSIVE ENCEPHALOPATHY does not always result in clinical improvement in the patient's central nervous system.,ARTERIAL HYPERTENSION,HYPERTENSIVE ENCEPHALOPATHY
502251747,7/11/2014 14:50:00,,1320762871,7/11/2014 14:49:51,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],(TRISOMY,s,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 14:52:59,,1320764082,7/11/2014 14:52:42,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],involved,N/A,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 14:54:41,,1320764766,7/11/2014 14:54:24,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AND may,n/a,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:08:08,,1320771232,7/11/2014 15:07:37,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],Amyloid B protein/amyloid A4,N/A,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:09:17,,1320771848,7/11/2014 15:08:07,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],peptide present AND may be involved,n/a,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:26:47,,1320780415,7/11/2014 15:25:42,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,Both are diseases treated with the same treatments.,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:29:06,,1320781214,7/11/2014 15:26:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[ASSOCIATED_WITH],[ASSOCIATED_WITH],AND may be involved in the pathogenesis of,N/A,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:37:16,,1320784733,7/11/2014 15:36:46,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,They are separate conditions,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:37:38,,1320784823,7/11/2014 15:37:05,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],AND,n/a,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:40:58,,1320785942,7/11/2014 15:39:52,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[LOCATION],[LOCATION],"neuritic plaques, neurofibrillary tangles and cerebrovascular deposits",n/a,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 15:56:05,,1320793274,7/11/2014 15:54:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 16:17:55,,1320800776,7/11/2014 16:16:11,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[CAUSES],[CAUSES],AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE,N/A,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 16:18:05,,1320800834,7/11/2014 16:17:33,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[ASSOCIATED_WITH],[ASSOCIATED_WITH],protein/amyloid peptide neuritic neurofibrillary ALZHEIMER'S DISEASE,na,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 16:18:46,,1320800986,7/11/2014 16:17:56,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[ASSOCIATED_WITH],[ASSOCIATED_WITH],involved in the pathogenesis of,involved in the pathogenesis of,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251747,7/11/2014 16:19:48,,1320801270,7/11/2014 16:19:02,clixsense,1.0,17648398,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients AND,N/A,241,165,259,200,-1,RO-has_manifestation,906082-FS1,"Amyloid B protein/amyloid A4 is a peptide present in the neuritic plaques, neurofibrillary tangles and cerebrovascular deposits in patients with Alzheimer's disease AND DOWN'S SYNDROME (TRISOMY 21) AND may be involved in the pathogenesis of ALZHEIMER'S DISEASE",ALZHEIMER'S DISEASE,AND DOWN'S SYNDROME (TRISOMY 21) AND
502251748,7/11/2014 14:47:44,,1320761987,7/11/2014 14:47:31,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],classical,nmmn,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 14:51:34,,1320763552,7/11/2014 14:51:24,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",and,n/a,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 14:51:47,,1320763636,7/11/2014 14:51:05,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[IS_A],[IS_A],is a,n/a,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 14:59:04,,1320766611,7/11/2014 14:58:28,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],RETARDATION,NONE,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 14:59:30,,1320766823,7/11/2014 14:57:09,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[IS_A],[IS_A],is a,N/A,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 15:12:55,,1320773817,7/11/2014 15:12:20,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],"classical multiple malformation,",na,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 15:18:37,,1320776294,7/11/2014 15:17:00,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],malformation syndrome,n/a,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 15:47:26,,1320787989,7/11/2014 15:46:57,instagc,1.0,13763729,USA,"","",75.182.89.225,[IS_A],[IS_A],"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME",N/A,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 15:59:33,,1320794451,7/11/2014 15:58:54,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[IS_A],[IS_A],is,n/a,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 16:13:08,,1320799239,7/11/2014 16:12:27,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[CAUSES],[CAUSES],"SLOS a classical multiple malformation, MENTAL RETARDATION SYNDROME",nsa,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 16:13:59,,1320799479,7/11/2014 16:13:02,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[MANIFESTATION] [SIDE_EFFECT],"[MANIFESTATION]
[SIDE_EFFECT]","classical multiple malformation,","classical multiple malformation,",43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 16:26:56,,1320803160,7/11/2014 16:25:45,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[IS_A],[IS_A],SLOS is MENTAL RETARDATION SYNDROME,N/A,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 16:35:06,,1320806075,7/11/2014 16:34:39,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[IS_A],[IS_A],is a,N/A,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 16:46:31,,1320809640,7/11/2014 16:45:56,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SLOS MENTAL RETARDATION SYNDROME,na,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251748,7/11/2014 16:51:03,,1320810901,7/11/2014 16:50:46,neodev,1.0,18517457,GBR,"","",86.29.147.112,[IS_A],[IS_A],is a,N/a,43,0,69,3,1,RO-has_manifestation,906365-FS1,"SLOS is a classical multiple malformation, MENTAL RETARDATION SYNDROME and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis.",MENTAL RETARDATION SYNDROME,SLOS
502251749,7/11/2014 14:50:20,,1320762978,7/11/2014 14:50:12,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[LOCATION],[LOCATION],and,z,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 14:53:13,,1320764141,7/11/2014 14:53:01,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],sharing,N/A,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 15:06:28,,1320770464,7/11/2014 15:04:17,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[LOCATION],[LOCATION],site,na,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 15:16:04,,1320775261,7/11/2014 15:13:46,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[MANIFESTATION],[MANIFESTATION],sharing the non caseating granuloma,n/a,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 15:31:14,,1320781960,7/11/2014 15:30:28,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],sharing HALLMARK,n/a,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 15:56:35,,1320793460,7/11/2014 15:55:06,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[LOCATION],[LOCATION],LUNG,N/A,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:09:06,,1320798030,7/11/2014 16:07:49,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[SYMPTOM],[SYMPTOM],"DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK",N/A,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:10:34,,1320798455,7/11/2014 16:09:41,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[ASSOCIATED_WITH] [MANIFESTATION],"[MANIFESTATION]
[ASSOCIATED_WITH]","PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing PATHOLOGICAL LUNG HALLMARK",na,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:16:04,,1320800014,7/11/2014 16:15:42,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],sharing,N/A,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:34:10,,1320805422,7/11/2014 16:33:48,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[SYMPTOM],[SYMPTOM],sharing the,N/A,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:47:59,,1320810093,7/11/2014 16:47:06,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[NONE],[NONE],na,na,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:53:00,,1320811470,7/11/2014 16:52:34,neodev,1.0,18517457,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],sharing the,N/a,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:53:31,,1320811635,7/11/2014 16:53:25,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 16:55:54,,1320812511,7/11/2014 16:54:19,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[PART_OF],[PART_OF],sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma,N/a,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251749,7/11/2014 17:00:30,,1320814487,7/11/2014 16:58:08,prodege,1.0,11616695,GBR,H2,Skelmersdale,92.28.88.16,[ASSOCIATED_WITH] [SYMPTOM],"[SYMPTOM]
[ASSOCIATED_WITH]",sharing,I did not select [NONE].,106,18,131,73,1,RO-disease_has_primary_anatomic_site,902241-FS1,"Chronic beryllium DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT chronic disorders, sharing the PATHOLOGICAL LUNG HALLMARK of the non caseating granuloma and the immunological feature of T cell activation at the site of disease.",PATHOLOGICAL LUNG HALLMARK,DISEASE (CBD) AND PULMONARY SARCOIDOSIS ARE TWO DISTINCT
502251750,7/11/2014 14:46:01,,1320761374,7/11/2014 14:45:51,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[SYMPTOM],[SYMPTOM],"Henle,",hjhj,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 14:53:05,,1320764104,7/11/2014 14:52:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients,n/a,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 14:54:52,,1320764867,7/11/2014 14:54:40,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],excessive,N/A,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:01:36,,1320767724,7/11/2014 15:01:28,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],ALLERGIC,NONE,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:03:01,,1320768478,7/11/2014 15:02:10,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[ASSOCIATED_WITH],[ASSOCIATED_WITH],in patients with,N/A,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:14:20,,1320774476,7/11/2014 15:12:57,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],in patients with SULFA ALLERGY,na,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:29:26,,1320781319,7/11/2014 15:28:22,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[SYMPTOM],[SYMPTOM],patients with,n/a,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:31:14,,1320781957,7/11/2014 15:30:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS with SULFA ALLERGY,N/A,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:33:34,,1320782850,7/11/2014 15:33:26,instagc,1.0,27753923,GBR,"","",188.29.78.53,[LOCATION],[LOCATION],DIURESIS ELECTROLYTE,n/a,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:35:46,,1320784174,7/11/2014 15:35:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PART_OF],[PART_OF],in patients with,N/A,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:39:50,,1320785520,7/11/2014 15:38:32,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[SYMPTOM],[SYMPTOM],ALLERGIC REACTIONS in patients,n/a,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:43:33,,1320786654,7/11/2014 15:41:27,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[SIDE_EFFECT],[SIDE_EFFECT],Excessive Use may precipitate,n/a,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 15:48:42,,1320788549,7/11/2014 15:47:38,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],in patients with,N/A,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 16:02:29,,1320795296,7/11/2014 15:59:55,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],in patients with,n/a,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251750,7/11/2014 16:10:17,,1320798403,7/11/2014 16:09:27,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],precipitate hemodynamic collapse.,precipitate hemodynamic collapse.,371,438,419,450,1,RO-cause_of,900184-FS1,"Some practitioners do, however, use digoxin in this setting Diuretic agents Furosemide (Lasix)  Inhibits sodium and chloride absorption in the proximal tubules, distal tubules, and loop of Henle, thereby leading to diuresis  Usual dose is 20 80 mg/d adjusted to achieve desired diuretic effect  Relief of edema or ascites in the setting of right heart failure  Excessive DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS in patients with SULFA ALLERGY  Use with caution as excessive diuresis may precipitate hemodynamic collapse.",DIURESIS ELECTROLYTE DEPLETION ALLERGIC REACTIONS,SULFA ALLERGY
502251751,7/11/2014 14:55:26,,1320765065,7/11/2014 14:55:14,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],the,n/a,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 15:02:07,,1320767957,7/11/2014 15:01:37,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],AMOXYCILLIN,NONE,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 15:31:19,,1320781973,7/11/2014 15:30:02,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],TRIAL IN the TREATMENT OF,N/A,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 15:35:17,,1320783934,7/11/2014 15:34:27,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],the,N/A,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 15:35:36,,1320784083,7/11/2014 15:35:27,instagc,1.0,27753923,GBR,"","",188.29.78.53,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],ELDERLY.,n/a,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 15:37:32,,1320784809,7/11/2014 15:37:14,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],TREATMENT,n\a,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 15:39:27,,1320785404,7/11/2014 15:38:31,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],CONTROLLED TRIAL NORFLOXACIN AMOXYCILLIN TREATMENT UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.,N/A,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:02:18,,1320795279,7/11/2014 16:01:15,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],IN the TREATMENT OF,N/A,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:04:14,,1320795813,7/11/2014 16:03:54,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],TREATMENT,n/a,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:22:32,,1320802054,7/11/2014 16:21:59,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Pathy A CONTROLLED OF NORFLOXACIN AND AMOXYCILLIN the TREATMENT URINARY TRACT INFECTION THE ELDERLY.,na,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:32:47,,1320805004,7/11/2014 16:32:11,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],CONTROLLED TRIAL,N/A,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:37:14,,1320806645,7/11/2014 16:35:52,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[OTHER],[OTHER],IN the,IN the,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:38:38,,1320807074,7/11/2014 16:36:53,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],AMOXYCILLIN TREATMENT URINARY TRACT INFECTION,na,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:53:37,,1320811649,7/11/2014 16:53:32,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251751,7/11/2014 16:53:47,,1320811668,7/11/2014 16:53:27,neodev,1.0,18517457,GBR,"","",86.29.147.112,[TREATS],[TREATS],A CONTROLLED TRIAL,Na/,90,35,154,84,1,RO-may_treat,907612-FS1,"Hill S, Yeates M, Pathy J et al. A CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN the TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY.",TREATMENT OF UNCOMPLICATED URINARY TRACT INFECTION IN THE ELDERLY,CONTROLLED TRIAL OF NORFLOXACIN AND AMOXYCILLIN IN
502251752,7/11/2014 14:54:39,,1320764746,7/11/2014 14:54:30,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],that,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 14:54:57,,1320764886,7/11/2014 14:54:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],is a life,n/a,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:06:45,,1320770589,7/11/2014 15:06:29,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[CAUSES],[CAUSES],caused by,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:09:33,,1320772061,7/11/2014 15:08:48,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[CAUSES],[CAUSES],caused by mutations,n/a,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:26:48,,1320780434,7/11/2014 15:24:10,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[MANIFESTATION] [TREATS],"[TREATS]
[MANIFESTATION]",is caused,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:30:26,,1320781748,7/11/2014 15:29:59,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],caused,n\a,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:32:41,,1320782516,7/11/2014 15:32:05,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],caused by,na,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:36:40,,1320784568,7/11/2014 15:36:30,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CAUSES],[CAUSES],HAEMOPHILIA A,n/a,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:36:45,,1320784595,7/11/2014 15:36:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[MANIFESTATION],[MANIFESTATION],caused by mutations,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 15:59:54,,1320794650,7/11/2014 15:59:34,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[LOCATION],[LOCATION],in the,n/a,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 16:12:48,,1320799146,7/11/2014 16:12:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[CAUSES],[CAUSES],caused by,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 16:14:36,,1320799697,7/11/2014 16:14:04,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[CAUSES],[CAUSES],HAEMOPHILIA A caused mutations the factor GENE.,na,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 16:21:40,,1320801753,7/11/2014 16:20:49,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[CAUSES],[CAUSES],HAEMOPHILIA A is caused by mutations in VIII (FVIII) GENE.,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 16:30:27,,1320804319,7/11/2014 16:29:36,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[SYMPTOM],[SYMPTOM],caused by mutations,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251752,7/11/2014 16:30:59,,1320804456,7/11/2014 16:30:43,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],caused,N/A,25,134,37,150,-1,RO-has_manifestation,906205-FS1,"In its most severe form, HAEMOPHILIA A is a life threatening haemorrhagic bleeding disorder that is caused by mutations in the factor VIII (FVIII) GENE.",HAEMOPHILIA A,VIII (FVIII) GENE
502251753,7/11/2014 14:51:31,,1320763534,7/11/2014 14:51:16,prodege,1,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],concentration,you selected [,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 14:54:24,,1320764608,7/11/2014 14:53:55,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],simple mask;,n/a,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 14:55:46,,1320765175,7/11/2014 14:55:34,clixsense,1,17950689,GBR,X5,Cardiff,89.168.38.216,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],Improved,NONE,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:03:13,,1320768555,7/11/2014 15:02:25,clixsense,1,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],Improved,na,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:21:06,,1320777693,7/11/2014 15:18:38,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[NONE],[NONE],n/a,It is just stating two separate things. No oxygen toxicity and al oxygen concentration,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:35:15,,1320783907,7/11/2014 15:34:40,instagc,1,18531561,CAN,ON,Mississauga,99.229.185.45,[ASSOCIATED_WITH],[ASSOCIATED_WITH],arteriAL OXYGEN SATURATION NO OXYGEN TOXICIty,n/a,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:35:49,,1320784193,7/11/2014 15:35:38,instagc,1.0,27753923,GBR,"","",188.29.78.53,[MANIFESTATION],[MANIFESTATION],"canula; L/min,",n/a,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:39:20,,1320785367,7/11/2014 15:37:16,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NO,N/A,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:39:52,,1320785547,7/11/2014 15:36:49,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],None,"It's all part of the same measure, not two different things.",100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:43:05,,1320786503,7/11/2014 15:40:45,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],at this,n/a,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 15:48:54,,1320788648,7/11/2014 15:47:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[CONTRAINDICATES],[CONTRAINDICATES],OXYGEN SATURATION NO OXYGEN TOXICIty,N/A,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 16:18:47,,1320800989,7/11/2014 16:18:20,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SIDE_EFFECT],[SIDE_EFFECT],NO OXYGEN TOXICIty,N/A,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 16:22:51,,1320802134,7/11/2014 16:22:14,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 16:30:15,,1320804243,7/11/2014 16:28:51,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[NONE],[NONE],n/a,The words that were presented were not properly selected. Parts of the words were missing.,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251753,7/11/2014 16:32:35,,1320804915,7/11/2014 16:31:30,prodege,1,12635833,CAN,"","",47.55.233.55,[NONE],[NONE],N/A,Sentence does not make sense.,100,122,119,137,-1,RO-has_causative_agent,903578-FS1,"HAPE, 2 6 L/min nasal canula; &gt;5 L/min, simple mask; 10 15 L/min, reservoir mask  Improved arteriAL OXYGEN SATURATION  NO OXYGEN TOXICIty at this oxygen concentration  tvml 3tvml ; tvml 87tvml ; tvml 142tvml.",AL OXYGEN SATURATION,NO OXYGEN TOXICI
502251754,7/11/2014 14:46:54,,1320761662,7/11/2014 14:46:45,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],fatiguability,hjhj,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 14:54:40,,1320764756,7/11/2014 14:54:08,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],GRAVIS,NONE,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 14:56:35,,1320765542,7/11/2014 14:56:25,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],studied,N/A,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 14:57:17,,1320765819,7/11/2014 14:57:07,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were studied,n/a,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:00:42,,1320767296,7/11/2014 14:59:38,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],recovery,na,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:28:20,,1320780917,7/11/2014 15:27:21,instagc,1,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],administration,n/a,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:32:01,,1320782249,7/11/2014 15:29:49,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],administration were studied,n/a,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:36:48,,1320784613,7/11/2014 15:36:41,instagc,1.0,27753923,GBR,"","",188.29.78.53,[PREVENTS],[PREVENTS],following maximal,n/a,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:39:47,,1320785507,7/11/2014 15:39:21,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[TREATS],[TREATS],with,N/A,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:41:01,,1320785947,7/11/2014 15:39:53,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],after administration of Tensilon,N/A,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:44:02,,1320786838,7/11/2014 15:43:34,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[TREATS],[TREATS],administration of,n/a,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:46:36,,1320787661,7/11/2014 15:45:16,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",administration of Tensilon,na,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:52:40,,1320791433,7/11/2014 15:52:16,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],administration of Tensilon,n/a,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 15:59:00,,1320794254,7/11/2014 15:57:41,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],after administration of,N/A,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251754,7/11/2014 16:25:45,,1320802876,7/11/2014 16:24:15,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[TREATS],[TREATS],after administration of Tensilon (EDROPHONIUM CHLORIDE) in patients with MYASTHENIA GRAVIS,N/A,178,122,194,143,1,RO-may_diagnose,906603-FS1,Orbicularis oculi fatiguability following maximal voluntary contraction and its recovery after administration of Tensilon (EDROPHONIUM CHLORIDE) were studied in 13 patients with MYASTHENIA GRAVIS (MG) and 8 normal controls.,MYASTHENIA GRAVIS,(EDROPHONIUM CHLORIDE)
502251755,7/11/2014 14:46:44,,1320761610,7/11/2014 14:46:31,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],apparently,nhjh,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 14:58:26,,1320766352,7/11/2014 14:57:28,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[CAUSES],[CAUSES],MYELOSIS,NONE,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:01:25,,1320767642,7/11/2014 15:00:30,prodege,1,26783464,GBR,I6,Milton Keynes,86.169.214.241,[OTHER],[OTHER],that a diagnosis of,N/A,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:16:54,,1320775518,7/11/2014 15:16:10,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diagnosis,na,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:31:15,,1320781961,7/11/2014 15:31:04,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CAUSES],[CAUSES],MEGAKARYOCYTIC MYELOSIS,n/a,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:32:48,,1320782547,7/11/2014 15:32:16,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,Different conditions,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:33:28,,1320782825,7/11/2014 15:32:15,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],diagnosis,n/a,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:34:11,,1320783265,7/11/2014 15:32:41,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,[NONE],[NONE],N/A,MYELOFIBROSIS was used to rule out one diagnosis and lead to the correct diagnosis - hence no relation.,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:43:47,,1320786773,7/11/2014 15:43:06,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],so different from that seen,n/a,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:46:56,,1320787790,7/11/2014 15:45:39,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],acute granulocytic leukemia MYELOFIBROSIS diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.,N/A,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 15:58:13,,1320794036,7/11/2014 15:56:36,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[OTHER],[OTHER],so different from that seen in,Two different diseases,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 16:03:32,,1320795568,7/11/2014 16:02:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 16:07:32,,1320797181,7/11/2014 16:06:02,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES] [SYMPTOM] [MANIFESTATION],"[CAUSES]
[SYMPTOM]
[MANIFESTATION]",proliferation of megakaryocytes,proliferation of megakaryocytes,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 16:22:46,,1320802114,7/11/2014 16:21:52,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],so different,N/A,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251755,7/11/2014 16:28:25,,1320803648,7/11/2014 16:27:58,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],diagnosis,N/A,136,170,148,198,-1,RO-disease_may_have_finding,902524-FS1,"There was a severe, apparently neoplastic proliferation of megakaryocytes so different from that seen in acute granulocytic leukemia or MYELOFIBROSIS that a diagnosis of ACUTE MEGAKARYOCYTIC MYELOSIS was warranted.",MYELOFIBROSIS,ACUTE MEGAKARYOCYTIC MYELOSIS
502251756,7/11/2014 14:51:03,,1320763341,7/11/2014 14:49:26,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[OTHER],[OTHER],detected,n/a,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 14:55:43,,1320765153,7/11/2014 14:55:20,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],sensitively,N/AN/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 14:58:17,,1320766244,7/11/2014 14:57:56,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],with the combined,n/a,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:02:21,,1320768100,7/11/2014 15:02:08,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],DEXAMETHASONE,NONE,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:07:08,,1320770726,7/11/2014 15:06:46,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detected,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:13:45,,1320774178,7/11/2014 15:12:52,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],sensitively detected with test.,n/a,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:26:04,,1320780146,7/11/2014 15:25:03,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test.,na,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:33:20,,1320782780,7/11/2014 15:32:49,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],sensitively detected,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:38:58,,1320785276,7/11/2014 15:36:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],test.,n/a,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 15:46:00,,1320787470,7/11/2014 15:45:20,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detected with,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 16:12:19,,1320799003,7/11/2014 16:11:38,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],sensitively detected with,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 16:16:10,,1320800030,7/11/2014 16:13:54,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEPRESSION can be detected with DEXAMETHASONE test.,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 16:20:37,,1320801479,7/11/2014 16:19:56,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detected,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 16:31:40,,1320804639,7/11/2014 16:31:23,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],detected,N/A,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251756,7/11/2014 16:47:05,,1320809799,7/11/2014 16:46:31,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],DEPRESSION DEXAMETHASONE,na,122,190,131,202,1,RO-may_diagnose,906529-FS1,Impaired regulation of the hypothalamus pituitary adrenocortical (HPA) system is a consistent finding among patients with DEPRESSION which can be most sensitively detected with the combined DEXAMETHASONE (dex)/corticotrophin releasing hormone (CRH) test.,DEPRESSION,DEXAMETHASONE
502251757,7/11/2014 14:50:30,,1320763074,7/11/2014 14:50:21,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CARCINOMA,x,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 14:53:17,,1320764156,7/11/2014 14:53:06,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,n/a,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 14:55:43,,1320765148,7/11/2014 14:54:43,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,there is no relation the are both examples that require the same action,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 14:57:27,,1320765874,7/11/2014 14:57:17,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[CAUSES],[CAUSES],CARCINOMA,NONE,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 15:16:08,,1320775278,7/11/2014 15:15:11,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[IS_A],[IS_A],or,na,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 15:29:49,,1320781507,7/11/2014 15:28:07,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[NONE],[NONE],n/a,two separate medical issues,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 15:30:28,,1320781760,7/11/2014 15:29:28,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,They are separate things that warrant attention in pregnancy - not directly related,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 15:35:02,,1320783810,7/11/2014 15:34:54,instagc,1.0,27753923,GBR,"","",188.29.78.53,[PREVENTS],[PREVENTS],SITU warrants,n/a,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 15:43:48,,1320786776,7/11/2014 15:43:26,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CARCINOMA IN SITU,N/A,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 15:50:42,,1320789860,7/11/2014 15:50:01,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,Two different conditions. No indication that they are related.,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 16:00:16,,1320794761,7/11/2014 15:59:26,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation,N/A,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 16:18:42,,1320800962,7/11/2014 16:18:06,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[OTHER],[OTHER],SEVERE or CARCINOMA IN SITU warrants further evaluation,na,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 16:24:57,,1320802678,7/11/2014 16:24:05,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",warrants further evaluation,warrants further evaluation,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 16:28:02,,1320803512,7/11/2014 16:27:21,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[PART_OF],[PART_OF],SEVERE DYSPLASIA CARCINOMA IN SITU,n/a,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251757,7/11/2014 16:31:22,,1320804525,7/11/2014 16:31:05,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],or,N/A,0,20,15,36,-1,RO-disease_has_finding,901558-FS1,"SEVERE DYSPLASIA or CARCINOMA IN SITU warrants further evaluation during pregnancy; colposcopy is usually accurate, but sometimes biopsy is necessary.",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251758,7/11/2014 14:50:06,,1320762898,7/11/2014 14:49:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],had evidence of,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 14:50:46,,1320763200,7/11/2014 14:50:08,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[TREATS],[TREATS],HEPATOMA,NONE,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 14:52:37,,1320763970,7/11/2014 14:52:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],56% had,n/a,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 15:31:12,,1320781956,7/11/2014 15:30:44,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],evidence of,na,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 15:33:42,,1320782950,7/11/2014 15:33:21,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],56% had evidence,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 15:36:46,,1320784609,7/11/2014 15:36:18,instagc,1.0,13763729,USA,"","",75.182.89.225,[SYMPTOM],[SYMPTOM],HEPATOMA 56% had evidence of HEPATOMEGALY,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 15:46:41,,1320787683,7/11/2014 15:46:01,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[SYMPTOM],[SYMPTOM],56% had evidence of,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:02:20,,1320795280,7/11/2014 16:00:57,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],with HEPATOMA 56% had evidence of HEPATOMEGALY,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:14:02,,1320799529,7/11/2014 16:13:31,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",had evidence of,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:16:06,,1320800018,7/11/2014 16:15:50,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[LOCATION],[LOCATION],HEPATOMA 56% had evidence HEPATOMEGALY,na,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:26:50,,1320803153,7/11/2014 16:25:56,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[MANIFESTATION],[MANIFESTATION],evidence,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:33:05,,1320805068,7/11/2014 16:32:36,prodege,1.0,12635833,CAN,"","",47.55.233.55,[CAUSES],[CAUSES],had evidence of HEPATOMEGALY,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:33:10,,1320805100,7/11/2014 16:32:48,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[PART_OF],[PART_OF],had evidence,N/A,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:39:49,,1320807407,7/11/2014 16:39:16,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],had evidence,had evidence,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251758,7/11/2014 16:50:19,,1320810694,7/11/2014 16:49:59,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],HEPATOMA HEPATOMEGALY,na,52,23,63,30,1,RO-disease_may_have_finding,902609-FS1,Of those patients with HEPATOMA 56% had evidence of HEPATOMEGALY,HEPATOMEGALY,HEPATOMA
502251759,7/11/2014 14:46:20,,1320761480,7/11/2014 14:46:02,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],DYSPLASIAS,kjk,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 14:56:13,,1320765347,7/11/2014 14:56:03,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],"dysplasias,",N/A,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:03:58,,1320768939,7/11/2014 15:03:03,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[OTHER],[OTHER],diploid DNA histogram patterns,N/A,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:18:13,,1320776126,7/11/2014 15:16:55,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],six of 12,na,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:24:55,,1320779743,7/11/2014 15:23:54,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,they are both listed examples,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:31:26,,1320782030,7/11/2014 15:31:16,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],INTRAEPITHELIAL CARCINOMAS,n/a,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:32:52,,1320782575,7/11/2014 15:31:15,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diploid DNA histogram patterns were observed SEVERE DYSPLASIAS INTRAEPITHELIAL CARCINOMAS,N/A,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:37:40,,1320784842,7/11/2014 15:36:20,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[NONE],[NONE],n/a,separate medical issues,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:55:26,,1320793002,7/11/2014 15:53:44,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[ASSOCIATED_WITH],[ASSOCIATED_WITH],diploid DNA histogram patterns were observed SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS,na,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 15:59:25,,1320794430,7/11/2014 15:58:22,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],diploid DNA patterns were observed in SEVERE DYSPLASIAS INTRAEPITHELIAL CARCINOMAS,N/A,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 16:14:53,,1320799757,7/11/2014 16:14:16,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[NONE],[NONE],N/A,Different diseases,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 16:32:10,,1320804800,7/11/2014 16:31:41,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],were observed,N/A,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 16:36:53,,1320806600,7/11/2014 16:36:17,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[NONE],[NONE],na,na,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 16:52:33,,1320811322,7/11/2014 16:51:59,neodev,1.0,18517457,GBR,"","",86.29.147.112,[ASSOCIATED_WITH],[ASSOCIATED_WITH],In,N/a,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251759,7/11/2014 16:53:50,,1320811672,7/11/2014 16:53:45,prodege,1,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,176,204,192,229,-1,RO-disease_has_finding,901919-FS1,"In surgical specimens, diploid DNA histogram patterns were observed in 16 of 17 nonpathologic epithelia, two of seven mild dysplasias, 12 of 21 moderate dysplasias, nine of 18 SEVERE DYSPLASIAS six of 12 INTRAEPITHELIAL CARCINOMAS and nine of 22 advanced carcinomas.",SEVERE DYSPLASIAS,INTRAEPITHELIAL CARCINOMAS
502251760,7/11/2014 14:47:55,,1320762057,7/11/2014 14:47:45,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[CONTRAINDICATES],[CONTRAINDICATES],SEGMENTAL,nnmn,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 14:49:28,,1320762633,7/11/2014 14:49:13,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],CYCLOSPORINE,NONE,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 14:53:42,,1320764318,7/11/2014 14:53:32,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],NEPHROTIC SEGMENTAL GLOMERULOSCLEROSIS,n/a,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 14:57:37,,1320765940,7/11/2014 14:57:26,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],with,N/A,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:04:15,,1320769080,7/11/2014 15:03:15,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],RECEIVED,na,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:22:25,,1320778597,7/11/2014 15:21:07,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,n/a,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:30:37,,1320781810,7/11/2014 15:30:26,instagc,1.0,27753923,GBR,"","",188.29.78.53,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],GLOMERULOSCLEROSIS AND,n/a,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:36:35,,1320784545,7/11/2014 15:36:00,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[PART_OF],[PART_OF],with,n\a,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:40:44,,1320785850,7/11/2014 15:38:38,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[ASSOCIATED_WITH],[ASSOCIATED_WITH],including,n/a,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:45:19,,1320787216,7/11/2014 15:43:07,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,"They are two different conditions, there is no indication that they are realated.",132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:49:24,,1320788988,7/11/2014 15:48:09,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[TREATS],[TREATS],RECEIVED CYCLOSPORINE,na,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 15:57:41,,1320793844,7/11/2014 15:56:07,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 16:15:40,,1320799924,7/11/2014 16:15:16,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[NONE],[NONE],N/A,Different diseases,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 16:33:35,,1320805211,7/11/2014 16:32:11,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[NONE],[NONE],n/a,n/a,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251760,7/11/2014 16:39:13,,1320807208,7/11/2014 16:38:27,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[MANIFESTATION],[MANIFESTATION],including,including,132,41,191,82,1,RO-may_treat,908111-FS1,"Eighteen children with steroid resistant NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A (CsA), including 7 patients with minimal change DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH mesangial hypercellurarity.",DISEASE 4 WITH FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND 7 WITH,NEPHROTIC SYNDROME RECEIVED CYCLOSPORINE A
502251761,7/11/2014 14:50:58,,1320763306,7/11/2014 14:50:44,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 14:51:28,,1320763503,7/11/2014 14:51:10,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],and,N/A,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:03:43,,1320768836,7/11/2014 15:03:07,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],HEMIFACIAL MICROSOMIA,NONE,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:19:52,,1320776969,7/11/2014 15:18:15,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],This procedure has been used,na,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:27:20,,1320780557,7/11/2014 15:26:21,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[NONE],[NONE],n/a,both examples which get the same pocedure,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:30:24,,1320781744,7/11/2014 15:30:16,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CONTRAINDICATES],[CONTRAINDICATES],UNILATERAL HEMIFACIAL,n/a,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:35:08,,1320783839,7/11/2014 15:34:25,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[LOCATION],[LOCATION],procedure been used,n/a,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:36:02,,1320784287,7/11/2014 15:35:16,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,two different conditions,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:40:50,,1320785888,7/11/2014 15:40:15,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],UNILATERAL HEMIFACIAL MICROSOMIA BILATERAL MANDIBULAR HYPOPLASIA,N/A,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 15:47:37,,1320788056,7/11/2014 15:46:42,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[NONE],[NONE],N/A,Two different conditions. No indication that they are related.,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 16:04:38,,1320795934,7/11/2014 16:04:09,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],patients with UNILATERAL HEMIFACIAL MICROSOMIA and with BILATERAL MANDIBULAR HYPOPLASIA,n/A,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 16:14:02,,1320799516,7/11/2014 16:13:09,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[OTHER],[OTHER],This procedure has been used patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,na,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 16:22:13,,1320801943,7/11/2014 16:21:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],been used in,N/A,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 16:24:03,,1320802373,7/11/2014 16:23:22,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",has been used,has been used,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251761,7/11/2014 16:29:00,,1320803853,7/11/2014 16:28:48,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[NONE],[NONE],N/A,Different diseases,103,49,133,80,-1,RO-has_manifestation,906013-FS1,This procedure has been used in 87 patients with UNILATERAL HEMIFACIAL MICROSOMIA and 19 patients with BILATERAL MANDIBULAR HYPOPLASIA,BILATERAL MANDIBULAR HYPOPLASIA,UNILATERAL HEMIFACIAL MICROSOMIA
502251762,7/11/2014 14:54:42,,1320764785,7/11/2014 14:54:16,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],treatment,n/a,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:21:51,,1320778226,7/11/2014 15:21:25,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],treatment with,n/a,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:25:00,,1320779775,7/11/2014 15:24:29,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],with high dose METHOTREXATE,na,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:29:04,,1320781206,7/11/2014 15:28:42,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],with high dose,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:32:18,,1320782366,7/11/2014 15:32:00,instagc,1.0,27753923,GBR,"","",188.29.78.53,[MANIFESTATION],[MANIFESTATION],experience of,n/a,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:41:29,,1320786118,7/11/2014 15:40:51,instagc,1.0,13763729,USA,"","",75.182.89.225,[OTHER],[OTHER],treatment of OSTEOSARCOMA with high dose METHOTREXATE,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:44:18,,1320786933,7/11/2014 15:43:34,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[TREATS],[TREATS],the treatment of,n/a,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:55:05,,1320792891,7/11/2014 15:54:22,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[TREATS],[TREATS],the treatment with,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 15:56:45,,1320793516,7/11/2014 15:55:28,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[TREATS],[TREATS],in the treatment of OSTEOSARCOMA with high dose METHOTREXATE,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 16:09:25,,1320798144,7/11/2014 16:08:31,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [DIAGNOSE_BY_TEST_OR_DRUG],"[TREATS]
[DIAGNOSE_BY_TEST_OR_DRUG]",in the treatment,in the treatment,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 16:15:15,,1320799829,7/11/2014 16:14:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[TREATS],[TREATS],with high dose,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 16:19:06,,1320801072,7/11/2014 16:18:48,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[TREATS],[TREATS],treatment,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 16:20:51,,1320801555,7/11/2014 16:20:33,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[TREATS],[TREATS],OSTEOSARCOMA with high dose METHOTREXATE,na,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 16:36:00,,1320806333,7/11/2014 16:35:41,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[TREATS],[TREATS],treatment,N/A,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251762,7/11/2014 16:51:18,,1320810965,7/11/2014 16:50:45,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],OSTEOSARCOMA METHOTREXATE,na,114,142,125,153,1,RO-may_treat,908313-FS1,This paper will present the experience of the Department of Clinical Haematology and Oncology in the treatment of OSTEOSARCOMA with high dose METHOTREXATE and summarize other groups' experiences with various chemotherapy regimes.,OSTEOSARCOMA,METHOTREXATE
502251763,7/11/2014 14:50:10,,1320762910,7/11/2014 14:50:02,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[CONTRAINDICATES],[CONTRAINDICATES],samples,z,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 14:51:51,,1320763656,7/11/2014 14:51:35,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 14:54:17,,1320764590,7/11/2014 14:54:02,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],moderate 13,N/A,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 15:01:27,,1320767641,7/11/2014 15:00:51,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],lesion,NONE,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 15:30:42,,1320781835,7/11/2014 15:29:53,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,na,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 15:31:03,,1320781923,7/11/2014 15:30:50,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],SEVERE DYSPLASIA,n/a,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 15:33:30,,1320782840,7/11/2014 15:32:53,instagc,1.0,13763729,USA,"","",75.182.89.225,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"high grade squamous intraepithelial lesion tested positively telomerase activity, SEVERE DYSPLASIA CARCINOMA IN SITU",N/A,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 15:36:20,,1320784433,7/11/2014 15:35:09,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[NONE],[NONE],n/a,two separate medical issues,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 15:40:17,,1320785681,7/11/2014 15:39:48,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[NONE],[NONE],N/A,separate conditions,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 16:11:05,,1320798623,7/11/2014 16:10:20,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES] [DIAGNOSE_BY_TEST_OR_DRUG],"[DIAGNOSE_BY_TEST_OR_DRUG]
[CAUSES]",high grade squamous intraepithelial lesion,high grade squamous intraepithelial lesion,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 16:17:03,,1320800272,7/11/2014 16:16:39,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],"tested positively telomerase activity, DYSPLASIA and samples",na,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 16:22:25,,1320802019,7/11/2014 16:21:41,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],samples of SEVERE DYSPLASIA and samples of CARCINOMA IN SITU,N/A,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 16:23:22,,1320802240,7/11/2014 16:22:47,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],"positively for telomerase activity,",N/A,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 16:24:05,,1320802386,7/11/2014 16:23:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[IS_A],[IS_A],"telomerase activity,",N/A,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251763,7/11/2014 16:35:09,,1320806089,7/11/2014 16:34:34,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],SEVERE DYSPLASIA CARCINOMA IN SITU,na,196,235,211,251,-1,RO-disease_has_finding,901561-FS1,"Twenty five of 26 samples (96%) of high grade squamous intraepithelial lesion also tested positively for telomerase activity, including 10 of 10 samples of moderate dysplasia, 12 of 13 samples of SEVERE DYSPLASIA and 3 of 3 samples of CARCINOMA IN SITU",SEVERE DYSPLASIA,CARCINOMA IN SITU
502251764,7/11/2014 14:49:40,,1320762722,7/11/2014 14:49:30,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[CONTRAINDICATES],[CONTRAINDICATES],TRANSMISSION.,x,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 14:50:07,,1320762899,7/11/2014 14:49:29,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],HEPATITIS,NONE,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 14:52:53,,1320764047,7/11/2014 14:52:38,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],effective,n/a,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 15:15:08,,1320774890,7/11/2014 15:14:23,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[TREATS],[TREATS],vaccination,na,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 15:17:00,,1320775568,7/11/2014 15:16:06,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[PREVENTS],[PREVENTS],vaccine strategy,n/a,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 15:32:51,,1320782563,7/11/2014 15:32:32,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],HEPATITIS TRANSMISSION.,n/a,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 15:37:13,,1320784711,7/11/2014 15:36:36,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[TREATS],[TREATS],effective vaccine strategy,n/a,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:00:11,,1320794722,7/11/2014 15:59:27,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[PREVENTS],[PREVENTS],AN effective vaccine strategy,N/A,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:02:52,,1320795394,7/11/2014 16:02:31,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[OTHER],[OTHER],despite a low,n/a,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:12:26,,1320799030,7/11/2014 16:10:34,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[CAUSES],[CAUSES],despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.,na,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:20:48,,1320801545,7/11/2014 16:19:26,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[OTHER],[OTHER],AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.,N/A,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:21:19,,1320801680,7/11/2014 16:20:44,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[SYMPTOM],[SYMPTOM],a low,N/A,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:26:23,,1320803045,7/11/2014 16:25:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:29:24,,1320803990,7/11/2014 16:29:01,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[SIDE_EFFECT],[SIDE_EFFECT],despite a low,N/A,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251764,7/11/2014 16:35:49,,1320806295,7/11/2014 16:35:09,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [CONTRAINDICATES],"[TREATS]
[CONTRAINDICATES]",effective vaccine strategy,effective vaccine strategy,126,39,171,83,1,RO-may_prevent,907304-FS1,"Therefore, vaccination of all children AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN effective vaccine strategy despite a low INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION.",INCIDENCE OF VERTICAL HEPATITIS B TRANSMISSION,AT BIRTH WITH HEPATITIS B VACCINE COULD BE AN
502251765,7/11/2014 14:51:09,,1320763378,7/11/2014 14:50:50,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[CAUSES],[CAUSES],causative agent,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 14:51:54,,1320763675,7/11/2014 14:51:32,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[LOCATION],[LOCATION],VIRUS,"you selected [NONE] in STEP 1, explain why",0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 14:55:45,,1320765173,7/11/2014 14:55:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],agent of,n/a,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:00:50,,1320767361,7/11/2014 14:59:05,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[SYMPTOM],[SYMPTOM],VIRUS,NONE,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:04:51,,1320769431,7/11/2014 15:04:33,prodege,1.0,26783464,GBR,I6,Milton Keynes,86.169.214.241,[CAUSES],[CAUSES],causative agent of,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:34:26,,1320783405,7/11/2014 15:34:07,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[CAUSES],[CAUSES],the causative agent,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:34:48,,1320783663,7/11/2014 15:34:07,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CAUSES],[CAUSES],causative agent,na,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:37:03,,1320784669,7/11/2014 15:36:32,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CAUSES],[CAUSES],causative agent of,n/a,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:41:49,,1320786168,7/11/2014 15:41:29,instagc,1.0,13763729,USA,"","",75.182.89.225,[CAUSES],[CAUSES],VARIOLA MAJOR VIRUS causative agent of SMALLPOX,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:44:47,,1320787021,7/11/2014 15:44:18,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[CAUSES],[CAUSES],the causative agent,n/a,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:47:11,,1320787876,7/11/2014 15:46:37,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[CAUSES],[CAUSES],causative agent,na,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 15:54:20,,1320792606,7/11/2014 15:53:55,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CAUSES],[CAUSES],the causative agent,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 16:18:19,,1320800883,7/11/2014 16:18:02,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[CAUSES],[CAUSES],causative,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 16:23:05,,1320802170,7/11/2014 16:22:27,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[CAUSES],[CAUSES],VARIOLA MAJOR VIRUS the causative agent of SMALLPOX,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251765,7/11/2014 16:35:40,,1320806247,7/11/2014 16:35:27,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[CAUSES],[CAUSES],causative agent,N/A,0,43,18,50,1,RO-has_causative_agent,903785-FS1,VARIOLA MAJOR VIRUS the causative agent of SMALLPOX encodes the dual specificity H1 phosphatase.,VARIOLA MAJOR VIRUS,SMALLPOX
502251766,7/11/2014 14:48:26,,1320762267,7/11/2014 14:47:50,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],TETRACYCLINE,NONE,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 14:56:02,,1320765280,7/11/2014 14:55:44,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],Rationale:,N/A,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 14:56:25,,1320765485,7/11/2014 14:56:15,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [CAUSES],"[CAUSES]
[ASSOCIATED_WITH]",inhibitors,n/a,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:23:37,,1320779293,7/11/2014 15:21:54,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[CONTRAINDICATES],[CONTRAINDICATES],discontinued immediately with diagnosis of pregnancy,na,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:25:46,,1320780048,7/11/2014 15:24:56,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[ASSOCIATED_WITH],[ASSOCIATED_WITH],preferred,n/a,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:26:06,,1320780151,7/11/2014 15:24:06,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[CONTRAINDICATES],[CONTRAINDICATES],safer alternatives,n/a,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:27:24,,1320780585,7/11/2014 15:26:36,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[OTHER],[OTHER],alternatives preferred in,N/A,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:34:50,,1320783707,7/11/2014 15:34:42,instagc,1.0,27753923,GBR,"","",188.29.78.53,[PREVENTS],[PREVENTS],Gold Etretinate,n/a,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:37:19,,1320784765,7/11/2014 15:36:48,instagc,1.0,13763729,USA,"","",75.182.89.225,[NONE],[NONE],N/A,These are listed in an unrelated way.,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:39:59,,1320785595,7/11/2014 15:38:59,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,This is a medication that should not be taken during pregnancy,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 15:43:06,,1320786498,7/11/2014 15:41:57,vivatic,1.0,25451531,GBR,"","",83.67.28.193,[CONTRAINDICATES],[CONTRAINDICATES],medications that should be discontinued immediately with diagnosis of pregnancy,N/A,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 16:04:46,,1320795968,7/11/2014 16:04:15,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[CONTRAINDICATES],[CONTRAINDICATES],safer alternatives,n/a,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 16:13:31,,1320799340,7/11/2014 16:12:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[NONE],[NONE],N/A,No clear relationship.,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 16:19:00,,1320801051,7/11/2014 16:17:35,clixsense,1,17648398,GBR,K4,Plymouth,78.145.138.230,[CONTRAINDICATES],[CONTRAINDICATES],substituted alternatives,N/A,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251766,7/11/2014 16:19:42,,1320801255,7/11/2014 16:18:44,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[SIDE_EFFECT],[SIDE_EFFECT],medications with used for nonessential indications which are alternatives pregnancy.,na,399,370,410,378,1,RO-contraindicated_drug,901288-FS1,"B]  Specific Recommendation: ? Review the list of medications that should be discontinued before conception: ? Isotretinoin ? Methotrexate ? Thalidomide ? DES ? Misoprostol ? Penicillamine ? Gold ? Etretinate or acitretin ? Review the list of medications that should be discontinued immediately with diagnosis of pregnancy and substituted with alternatives preferred in PREGNANCY ? ACE inhibitors ? TETRACYCLINE ? Coumadin ? Methimazole ? Trimethadione  Rationale: ? These are all medications with known teratogenic effects used for nonessential indications (e.g., acne) or for which there are safer alternatives in pregnancy.",TETRACYCLINE,PREGNANCY
502251767,7/11/2014 14:49:17,,1320762552,7/11/2014 14:49:01,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[ASSOCIATED_WITH],[ASSOCIATED_WITH],has,mm,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 14:52:09,,1320763779,7/11/2014 14:51:51,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH] [LOCATION],"[LOCATION]
[ASSOCIATED_WITH]",because,n/a,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 15:03:06,,1320768495,7/11/2014 15:02:30,clixsense,1.0,17950689,GBR,X5,Cardiff,89.168.38.216,[PREVENTS],[PREVENTS],DISEASE,NONE,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 15:08:27,,1320771388,7/11/2014 15:06:29,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],CHRONIC RELAPSING,na,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 15:30:14,,1320781685,7/11/2014 15:30:06,instagc,1.0,27753923,GBR,"","",188.29.78.53,[SYMPTOM],[SYMPTOM],MODEL OF,n/a,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 15:40:54,,1320785911,7/11/2014 15:40:18,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[SYMPTOM],[SYMPTOM],because of its,N/A,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 15:51:17,,1320790298,7/11/2014 15:49:23,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[MANIFESTATION],[MANIFESTATION],A MODEL OF,n/a,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 15:57:47,,1320793890,7/11/2014 15:56:52,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS,na,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:00:21,,1320794747,7/11/2014 15:59:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[SYMPTOM] [MANIFESTATION],"[SYMPTOM]
[MANIFESTATION]",because of its,N/A,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:00:56,,1320794935,7/11/2014 16:00:16,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[SYMPTOM],[SYMPTOM],A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS,N/A,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:16:46,,1320800181,7/11/2014 16:15:43,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[CAUSES],[CAUSES],because of,because of,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:28:56,,1320803830,7/11/2014 16:28:27,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[PART_OF],[PART_OF],because of its,N/A,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:49:58,,1320810577,7/11/2014 16:49:28,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MODEL OF ATOPIC DISEASE CHRONIC RELAPSING ATOPIC DERMATITIS,na,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:53:12,,1320811542,7/11/2014 16:53:06,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251767,7/11/2014 16:53:27,,1320811606,7/11/2014 16:53:01,neodev,1.0,18517457,GBR,"","",86.29.147.112,[MANIFESTATION],[MANIFESTATION],has been proposed as,N/a,89,48,123,72,-1,RO-cause_of,900111-FS1,The Basenji greyhound (BG) has been proposed as A MODEL OF ATOPIC DISEASE because of its CHRONIC RELAPSING ATOPIC DERMATITIS as well as airway hyperresponsiveness.,CHRONIC RELAPSING ATOPIC DERMATITIS,A MODEL OF ATOPIC DISEASE
502251768,7/11/2014 14:48:59,,1320762435,7/11/2014 14:48:48,prodege,1.0,18960400,GBR,A2,Edgware,31.54.207.221,[MANIFESTATION],[MANIFESTATION],was,kjkj,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 14:50:23,,1320763015,7/11/2014 14:50:07,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],candidate,N/A,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 15:24:05,,1320779481,7/11/2014 15:22:25,prodege,1.0,28049280,USA,NC,Macclesfield,71.50.150.205,[PREVENTS],[PREVENTS],skin test from vaccination,n/a,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 15:24:28,,1320779599,7/11/2014 15:23:38,clixsense,1.0,15189335,GBR,I9,Norwich,86.155.45.231,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],prime candidate for a component of,na,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 15:31:40,,1320782116,7/11/2014 15:31:03,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[PART_OF],[PART_OF],is a prime candidate for a component,N/A,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 15:33:55,,1320783066,7/11/2014 15:33:44,instagc,1.0,27753923,GBR,"","",188.29.78.53,[CAUSES],[CAUSES],latent tuberculosis,n/a,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 15:58:32,,1320794127,7/11/2014 15:58:01,neodev,1.0,18755947,GBR,H2,Accrington,80.47.185.52,[TREATS],[TREATS],"antigen,",n/a,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:07:03,,1320797007,7/11/2014 16:05:50,prodege,1.0,17334212,CAN,NB,Fredericton,142.162.42.73,[PART_OF],[PART_OF],10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a component TUBERCULIN,N/A,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:17:30,,1320800463,7/11/2014 16:17:12,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[PART_OF],[PART_OF],component,N/A,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:27:00,,1320803186,7/11/2014 16:26:21,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],component of a new,N/A,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:27:28,,1320803366,7/11/2014 16:26:24,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,[LOCATION],[LOCATION],prime candidate for a component of,N/A,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:41:12,,1320807864,7/11/2014 16:40:30,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[TREATS] [PREVENTS],"[TREATS]
[PREVENTS]",is prime candidate for a component,is prime candidate for a component,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:45:55,,1320809464,7/11/2014 16:45:01,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[ASSOCIATED_WITH],[ASSOCIATED_WITH],MTSA (FOR TUBERCULOSIS ANTIGEN TUBERCULIN,na,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:53:04,,1320811489,7/11/2014 16:52:58,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251768,7/11/2014 16:54:17,,1320811846,7/11/2014 16:51:20,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[TREATS],[TREATS],candidate,None,34,124,76,133,1,RO-may_diagnose,906978-FS1,"The antigen, which was named MTSA 10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10) is a prime candidate for a component of a new TUBERCULIN that will allow discrimination by a skin test of latent M. tuberculosis infection from vaccination with BCG or from sensitization with environmental, nontuberculous mycobacteria.",10 (FOR M TUBERCULOSIS SPECIFIC ANTIGEN 10),TUBERCULIN
502251769,7/11/2014 14:54:02,,1320764449,7/11/2014 14:53:49,neodev,1.0,25224036,CAN,ON,Sudbury,67.204.218.187,[PART_OF],[PART_OF],oscillating,N/A,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 14:56:03,,1320765288,7/11/2014 14:55:46,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,[ASSOCIATED_WITH],[ASSOCIATED_WITH],and,n/a,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 15:11:22,,1320773220,7/11/2014 15:10:34,instagc,1.0,25901556,GBR,C3,Saint Ives,82.9.129.2,[CAUSES],[CAUSES],varies fluoride exposure,n/a,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 15:34:23,,1320783392,7/11/2014 15:33:31,instagc,1.0,13763729,USA,"","",75.182.89.225,[DIAGNOSE_BY_TEST_OR_DRUG],[DIAGNOSE_BY_TEST_OR_DRUG],BLOOD FLUORIDE CONCENTRATION DENTAL FLUOROSIS,N/A,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 15:36:27,,1320784508,7/11/2014 15:36:20,instagc,1.0,27753923,GBR,"","",188.29.78.53,[MANIFESTATION],[MANIFESTATION],fluoride the,n/a,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 15:42:56,,1320786425,7/11/2014 15:42:27,neodev,1.0,14861092,GBR,I2,Manchester,90.194.137.76,[ASSOCIATED_WITH],[ASSOCIATED_WITH],varies according to fluoride exposure and,N/A,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 15:48:15,,1320788326,7/11/2014 15:45:38,instagc,1.0,18531561,CAN,ON,Mississauga,99.229.185.45,[NONE],[NONE],n/a,two different conditions,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:21:21,,1320801682,7/11/2014 16:20:52,instagc,1.0,22653569,USA,TX,Frisco,99.122.166.44,[MANIFESTATION],[MANIFESTATION],BLOOD FLUORIDE CONCENTRATION varies according fluoride exposure DENTAL FLUOROSIS,na,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:24:44,,1320802621,7/11/2014 16:23:23,instagc,1.0,28301350,GBR,K4,Plymouth,78.145.138.230,[ASSOCIATED_WITH],[ASSOCIATED_WITH],would be similar,N/A,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:29:49,,1320804122,7/11/2014 16:29:24,zoombucks,1.0,5919735,USA,PA,Doylestown,173.49.91.231,[ASSOCIATED_WITH],[ASSOCIATED_WITH],related,N/A,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:37:49,,1320806846,7/11/2014 16:37:15,elite,1.0,28276268,USA,CA,San Diego,76.88.95.100,[MANIFESTATION],[MANIFESTATION],varies,varies,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:39:05,,1320807173,7/11/2014 16:38:39,instagc,1.0,21777979,USA,GA,Warner Robins,174.78.194.199,[CAUSES],[CAUSES],BLOOD FLUORIDE CONCENTRATION DENTAL FLUOROSIS,na,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:53:44,,1320811663,7/11/2014 16:53:38,prodege,1.0,12944140,GBR,C8,Croydon,92.21.54.140,[NONE],[NONE],na,na,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 16:54:25,,1320811881,7/11/2014 16:53:48,neodev,1.0,18517457,GBR,"","",86.29.147.112,[OTHER],[OTHER],present study,N/a,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
502251769,7/11/2014 17:01:06,,1320814810,7/11/2014 16:58:04,clixsense,1.0,8100278,USA,FL,Orlando,98.70.77.97,[ASSOCIATED_WITH] [PART_OF],"[ASSOCIATED_WITH]
[PART_OF]",varies according to fluoride exposure related to the amount enamel formed,Na,17,93,44,108,-1,RO-has_causative_agent,903506-FS1,"Considering that BLOOD FLUORIDE CONCENTRATION varies according to fluoride exposure and that DENTAL FLUOROSIS is related to the amount of enamel formed under a given fluoride dose, the present study investigated whether the fluorosis produced by an oscillating chronic fluoride dose would be similar to that caused by exposure to a constant dose, representing the mean of the oscillation during a given time.",BLOOD FLUORIDE CONCENTRATION,DENTAL FLUOROSIS
